Melinta Therapeutics (NASDAQ:MLNT) Earns Daily Media Sentiment Rating of 0.06

Media stories about Melinta Therapeutics (NASDAQ:MLNT) have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Melinta Therapeutics earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.1113939157435 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Shares of Melinta Therapeutics (NASDAQ MLNT) opened at $14.90 on Friday. The firm has a market capitalization of $322.28, a P/E ratio of -1.58 and a beta of 1.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.49 and a current ratio of 11.49. Melinta Therapeutics has a fifty-two week low of $10.25 and a fifty-two week high of $24.25.

A number of research firms recently issued reports on MLNT. Zacks Investment Research upgraded Melinta Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 17th. ValuEngine downgraded Melinta Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Gabelli upgraded Melinta Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 30th. Ladenburg Thalmann Financial Services upgraded Melinta Therapeutics from a “neutral” rating to a “buy” rating in a research note on Thursday, November 30th. Finally, Jefferies Group restated a “neutral” rating on shares of Melinta Therapeutics in a research note on Thursday, October 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. Melinta Therapeutics has an average rating of “Hold” and a consensus target price of $3.56.

In related news, Director Vatera Healthcare Partners Llc acquired 5,777,778 shares of the company’s stock in a transaction on Friday, January 5th. The stock was purchased at an average cost of $13.50 per share, with a total value of $78,000,003.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 31.50% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://stocknewstimes.com/2018/01/20/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-melinta-therapeutics-mlnt-stock-price.html.

About Melinta Therapeutics

Melinta Therapeutics, Inc develops and commercializes novel antibiotics designed to provide therapeutic solutions. The Company’s lead product is Baxdela, an antibiotic approved by the United States food and drug administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Insider Buying and Selling by Quarter for Melinta Therapeutics (NASDAQ:MLNT)

Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply